Clinical advances in hemophilia management (Q37900933)

25 August 2017

1 reference

title

Clinical advances in hemophilia management (English)

1 reference

25 August 2017

0 references

Anjali A Sharathkumar

series ordinal

1 reference

25 August 2017

Manuel Carcao

series ordinal

1 reference

25 August 2017

publication date

13 July 2011

1 reference

25 August 2017

published in

Pediatric Blood & Cancer

1 reference

25 August 2017

1 reference

25 August 2017

1 reference

25 August 2017

page(s)

910-920

1 reference

The history of haemophilia

25 August 2017

cites work

1 reference

The hemophilias--from royal genes to gene therapy

21 January 2018

1 reference

Thirty Years of Haemophilia Treatment in Oxford

21 January 2018

1 reference

FURTHER EXPERIENCE IN USE OF HUMAN ANTIHAEMOPHILIC GLOBULIN (H.A.H.G.) FOR THE CONTROL OF BLEEDING AFTER DENTAL EXTRACTION IN HAEMOPHILIC PATIENTS: A REPORT TO THE MEDICAL RESEARCH COUNCIL'S WORKING PARTY ON HUMAN ANTIHAEOMOPHILIC GLOBULIN

21 January 2018

1 reference

Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia

21 January 2018

1 reference

Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B.

21 January 2018

1 reference

Mortality rates, life expectancy, and causes of death in people with hemophilia A or B in the United Kingdom who were not infected with HIV.

21 January 2018

1 reference

Genetic mapping and diagnosis of haemophilia A achieved through a BclI polymorphism in the factor VIII gene

21 January 2018

1 reference

Isolation and characterization of a cDNA coding for human factor IX

21 January 2018

1 reference

Molecular cloning of a cDNA encoding human antihaemophilic factor

21 January 2018

1 reference

Nucleotide sequence of the gene for human factor IX (antihemophilic factor B)

21 January 2018

1 reference

Insight into the structure, function, and biosynthesis of factor VIII through recombinant DNA technology

21 January 2018

1 reference

The molecular basis of haemophilia A and B.

21 January 2018

1 reference

Haemophilia B: database of point mutations and short additions and deletions--eighth edition

21 January 2018

1 reference

Haemophilia A mutations in the UK: results of screening one-third of the population.

21 January 2018

1 reference

Haemophilia B: database of point mutations and short additions and deletions, 7th edition

21 January 2018

1 reference

A longitudinal study of orthopaedic outcomes for severe factor-VIII-deficient haemophiliacs. The Orthopaedic Outcome Study Group

21 January 2018

1 reference

Variability in clinical phenotype of severe haemophilia: the role of the first joint bleed.

21 January 2018

1 reference

Haemophilia and thrombophilia: an unexpected association!

21 January 2018

1 reference

Paradoxical hyperfibrinolysis is associated with a more intensely haemorrhagic phenotype in severe congenital haemophilia

21 January 2018

1 reference

The role of physical therapy and rehabilitation in the management of hemophilia in developing countries

21 January 2018

1 reference

Missense mutations and the magnitude of functional deficit: the example of factor IX.

21 January 2018

1 reference

Haemophilia B (sixth edition): a database of point mutations and short additions and deletions

21 January 2018

1 reference

Evidence that descendants of three founders constitute about 25% of hemophilia B in the United States

21 January 2018

1 reference

A less severe form of Haemophilia B Leyden

21 January 2018

1 reference

Female haemophilia A caused by skewed X inactivation

21 January 2018

1 reference

Christmas disease (haemophilia B) in a girl with deletion of the short arm of one X-chromosome (functional Turner syndrome)

21 January 2018

1 reference

Concomitant Turner syndrome and hemophilia A in a female with an idic(X)(p11) heterozygous at locus DXS52

21 January 2018

1 reference

Molecular mechanisms underlying hemophilia A phenotype in seven females

21 January 2018

1 reference

Severe haemophilia A in a female resulting from two de novo factor VIII mutations.

21 January 2018

1 reference

A case of female hemophilia with a 46,XXr karyotype studied with X-chromosome DNA probes

21 January 2018

1 reference

The molecular analysis of haemophilia A: a guideline from the UK haemophilia centre doctors' organization haemophilia genetics laboratory network

21 January 2018

1 reference

Treatment on demand--in vivo dose finding studies

21 January 2018

1 reference

Tranexamic acid combined with recombinant factor VIII increases clot resistance to accelerated fibrinolysis in severe hemophilia A.

21 January 2018

1 reference

21 January 2018

Inhibitor development.

1 reference

The North American Immune Tolerance Registry: contributions to the thirty-year experience with immune tolerance therapy

21 January 2018

1 reference

Inhibitors in factor IX deficiency a report of the ISTH-SSC international FIX inhibitor registry (1997-2006).

21 January 2018

1 reference

The mode of action of antibodies which destroy factor VIII. II. Antibodies which give complex concentration graphs

21 January 2018

1 reference

The mode of action of antibodies which destroy factor VIII. I. Antibodies which have second-order concentration graphs

21 January 2018

1 reference

Basic aspects of inhibitors to factors VIII and IX and the influence of non-genetic risk factors

21 January 2018

1 reference

Impact of inhibitor epitope profile on the neutralizing effect against plasma-derived and recombinant factor VIII concentrates in vitro.

21 January 2018

1 reference

Inhibitor treatment in haemophilias A and B: summary statement for the 2006 international consensus conference

21 January 2018

1 reference

Inhibitors in haemophilia: clinical aspects

21 January 2018

1 reference

Incidence of inhibitors in a cohort of 838 males with hemophilia A previously treated with factor VIII concentrates

21 January 2018

1 reference

Inhibitor development in hemophiliacs: the roles of genetic versus environmental factors

21 January 2018

1 reference

Inhibitor development in haemophilia B: an orphan disease in need of attention

21 January 2018

1 reference

Factor VIII inhibitors in haemophiliacs

21 January 2018

1 reference

Identification, pathogenesis, and treatment of factor inhibitors

21 January 2018

1 reference

The Malmö International Brother Study (MIBS): further support for genetic predisposition to inhibitor development in hemophilia patients

21 January 2018

1 reference

Human recombinant DNA-derived antihemophilic factor in the treatment of previously untreated patients with hemophilia A: final report on a hallmark clinical investigation

21 January 2018

1 reference

Polymorphisms in the TNFA gene and the risk of inhibitor development in patients with hemophilia A.

21 January 2018

1 reference

Polymorphisms in the IL10 but not in the IL1beta and IL4 genes are associated with inhibitor development in patients with hemophilia A.

21 January 2018

1 reference

Polymorphisms in the CTLA-4 gene and inhibitor development in patients with severe hemophilia A.

21 January 2018

1 reference

Impact of polymorphisms of the major histocompatibility complex class II, interleukin-10, tumor necrosis factor-alpha and cytotoxic T-lymphocyte antigen-4 genes on inhibitor development in severe hemophilia A.

21 January 2018

1 reference

Treatment characteristics and the risk of inhibitor development: a multicenter cohort study among previously untreated patients with severe hemophilia A.

21 January 2018

1 reference

Influence of the type of factor VIII concentrate on the incidence of factor VIII inhibitors in previously untreated patients with severe hemophilia A.

21 January 2018

1 reference

Early factor VIII exposure and subsequent inhibitor development in children with severe haemophilia A.

21 January 2018

1 reference

Environmental risk factors for inhibitor development in children with haemophilia A: a case-control study

21 January 2018

1 reference

Risk stratification for inhibitor development at first treatment for severe hemophilia A: a tool for clinical practice

21 January 2018

1 reference

21 January 2018

FEIBA: mode of action

1 reference

A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study

21 January 2018

1 reference

Single 270 microg kg(-1)-dose rFVIIa vs. standard 90 microg kg(-1)-dose rFVIIa and APCC for home treatment of joint bleeds in haemophilia patients with inhibitors: a randomized comparison

21 January 2018

1 reference

Monitoring the bioavailability of FEIBA with a thrombin generation assay.

21 January 2018

1 reference

Treatment of the bleeding inhibitor patient

21 January 2018

1 reference

Massive factor-VIII infusion in haemophiliac with factor-VIII inhibitor, high responder

21 January 2018

1 reference

Immune tolerance for the treatment of factor VIII inhibitors--twenty years' 'bonn protocol'.

21 January 2018

1 reference

The epidemiology of inhibitors in haemophilia A: a systematic review

21 January 2018

1 reference

Tolerance induction using the Malmö treatment model 1982-1995.

21 January 2018

1 reference

Induction of immune tolerance in haemophilia A inhibitor patients by the 'Bonn Protocol': predictive parameter for therapy duration and outcome

21 January 2018

1 reference

The international immune tolerance study: a multicenter prospective randomized trial in progress

21 January 2018

1 reference

Rituximab and immune tolerance in severe hemophilia A: a consecutive national cohort.

21 January 2018

1 reference

Immune tolerance induction with mycophenolate-mofetil in two children with haemophilia B and inhibitor

21 January 2018

1 reference

Inhibitor development in previously untreated patients with hemophilia A: a prospective long-term follow-up comparing plasma-derived and recombinant products

21 January 2018

1 reference

Immune tolerance in children with factors VIII and IX inhibitors: a single centre experience

21 January 2018

1 reference

International workshop on immune tolerance induction: consensus recommendations

21 January 2018

1 reference

Prophylactic treatment with activated prothrombin complex concentrate (FEIBA) reduces the frequency of bleeding episodes in paediatric patients with haemophilia A and inhibitors

21 January 2018

1 reference

Prophylactic treatment of haemophilia patients with inhibitors: clinical experience with recombinant factor VIIa in European Haemophilia Centres.

21 January 2018

1 reference

Randomized, prospective clinical trial of recombinant factor VIIa for secondary prophylaxis in hemophilia patients with inhibitors

21 January 2018

1 reference

The promise and challenges of bioengineered recombinant clotting factors

21 January 2018

1 reference

Functional roles of the factor VIII B domain

21 January 2018

1 reference

Characterization of a genetically engineered inactivation-resistant coagulation factor VIIIa

21 January 2018

1 reference

Prolonged activity of factor IX as a monomeric Fc fusion protein

21 January 2018

1 reference

Expression of factor VIII in recombinant and transgenic systems

21 January 2018

1 reference

Developing aptamers into therapeutics

21 January 2018

1 reference

Gene therapy, bioengineered clotting factors and novel technologies for hemophilia treatment

21 January 2018

1 reference

Ethical issues in haemophilia.

21 January 2018

1 reference

Gene therapy ethics and haemophilia: an inevitable therapeutic future?

21 January 2018

1 reference

Update on progress and hurdles in novel genetic therapies for hemophilia

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/PBC.23193

1 reference

25 August 2017

1 reference